^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:Erbitux (cetuximab) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    ERBITUX® is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of…Head and Neck Cancer…Locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    ERBITUX® is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of:...Locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy….Recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum based therapy with fluorouracil....Recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy.
    Secondary therapy:
    5-fluorouracil + Platinum alkylating agent
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck:...in combination with platinum-based chemotherapy for recurrent and/or metastatic disease.
    Secondary therapy:
    Chemotherapy
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Published date:
    11/01/2020
    Excerpt:
    Platinum/5-FU/cetuximab remains the standard therapy for recurrent/metastatic patients with SCCHN not expressing PD-L1 [I, A; ESMO-MCBS v1.1 score: 3]. TPeX is also a treatment option in this population [II, B].
    Secondary therapy:
    5-fluorouracil + Platinum alkylating agent
    DOI:
    10.1016/j.annonc.2020.07.011
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Excerpt:
    A summary of management strategies for recurrent and/or metastatic SCCHN...No platinum-based ChT during the last 6 months and PD-L1 assessment not carried out...Options...Methotrexate or taxane or cetuximab and/or BSC if contraindication to immunotherapy and unfit for platinum-based therapy...
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Title:

    Pan-Asian adaptation of the EHNSeESMOeESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck

    Excerpt:
    Recommendation 3: Treatment...In patients unfit for cisplatin, carboplatin combined with 5-FU or cetuximab concomitant to RT as well as hyperfractionated or accelerated RT without chemotherapy are treatment alternatives [II, A].
    Secondary therapy:
    carboplatin
    DOI:
    https://doi.org/10.1016/j.esmoop.2021.100309
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Excerpt:
    A summary of management strategies for recurrent and/or metastatic SCCHN...Pretreated with platinum based ChT within the last 6 months and immunotherapy naïve...Option...Taxane or methotrexate or cetuximab and/or BSC if contraindication to immunotherapy...
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Other combination regimens recommended by the panel for treatment of metastatic HNSCC include: 1) Cisplatin or carboplatin, plus 5-FU with cetuximab...3) cisplatin with cetuximab...or 5) cetuximab with a platinum and a taxane...
    Secondary therapy:
    cisplatin + 5-fluorouracil; carboplatin + 5-fluorouracil; cisplatin; Platinum alkylating agent
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Lancet Oncol
    Title:

    Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

    Published date:
    11/07/2009
    Excerpt:
    Updated median overall survival for patients treated with cetuximab and radiotherapy was 49·0 months (95% CI 32·8–69·5) versus 29·3 months (20·6–41·4) in the radiotherapy-alone group (hazard ratio [HR] 0·73, 95% CI 0·56–0·95; p=0·018). 5-year overall survival was 45·6% in the cetuximab-plus-radiotherapy group and 36·4% in the radiotherapy-alone group....For patients with LASCCHN, cetuximab plus radiotherapy significantly improves overall survival at 5 years compared with radiotherapy alone, confirming cetuximab plus radiotherapy as an important treatment option in this group of patients. Cetuximab-treated patients with prominent cetuximab-induced rash (grade 2 or above) have better survival than patients with no or grade 1 rash.
    DOI:
    https://doi.org/10.1016/S1470-2045(09)70311-0
    Trial ID:
    NCT00004227